Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Липотоксическое поражение миокарда при ожирении - Научно-практический журнал Cardioсоматика Том 8, №4 (2017)
Липотоксическое поражение миокарда при ожирении
Гриценко О.В., Чумакова Г.А., Ельчанинова С.А и др. Липотоксическое поражение миокарда при ожирении. CardioСоматика. 2017; 8 (4): 36–40.
________________________________________________
Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Аннотация
В статье рассматриваются основные механизмы развития липотоксического поражения миокарда и особенности морфологических и структурных изменений сердца при ожирении.
Ключевые слова: липотоксичность, липотоксическая кардиомиопатия, ожирение.
Key words: lipotoxicity, lipotoxicity cardiomyopathy, obesity.
Ключевые слова: липотоксичность, липотоксическая кардиомиопатия, ожирение.
________________________________________________
Key words: lipotoxicity, lipotoxicity cardiomyopathy, obesity.
Полный текст
Список литературы
1. Berrington de Gonzalez A, Hartge P, Cerhan JR et al. Body-mass index and mortality among 1.46 million white adults. N Engl J Med 2010; 363: 2211–9.
2. Wende AR, Abel ED. Lipotoxicity in the Heart. Biochim Biophys Acta 2010; 1801 (3): 311–9.
3. Асташкин Е.И., Глезер М.Г. Липотоксические эффекты в средце, наблюдаемые при ожирении. Артериальная гипертензия. 2009; 15 (3): 335–41. / Astashkin E.I., Glezer M.G. Lipotoksicheskie effekty v sredtse, nabliudaemye pri ozhirenii. Arterial'naia gipertenziia. 2009; 15 (3): 335–41. [in Russian]
4. Ritchie RH. Evidence for a causal role of oxidative stress in the myocardial complications of insulin resistance. Heart Lung Circ 2009; 18 (1): 11–8.
5. Drosatos K, Schulze PC. Cardiac Lipotoxicity: Molecular Pathways and Therapeutic Implications. Curr Heart Fail Rep 2013; 10 (2): 109–21.
6. Nanayakkara G, Kariharan T, Wang L et al. The cardio-protective signaling and mechanisms of adiponectin. Am J Cardiovasc Dis 2012; 2 (4): 253–66.
7. Haffar T, Bérubé-Simard F, Bousette N. Impaired fatty acid oxidation as a cause for lipotoxicity in cardiomyocytes. Biochem Biophys Res Commun 2015; 468 (1–2): 73–8.
8. Augustus AS, Buchanan J, Park TS et al. Loss of lipoprotein lipase-derived fatty acids leads to increased cardiac glucose metabolism and heart dysfunction. J Biol Chem 2006; 281: 8716–23.
9. Drosatos K, Bharadwaj KG, Lymperopoulos A et al. Cardiomyocyte lipids impair beta-adrenergic receptor function via pkc activation. Am J Physiol Endocrinol Metab 2011; 300: E489–499.
10. Gaborti B, Kober F, Jacquier A et al. Assessment of epicardial fat volume and myocardial triglyceride content in severely obese subjects: relationship to metabolic profile, cardiac function and visceral fat. Int J Obes (Lond) 2012; 36 (3): 422–30.
11. McGavock JM, Lingvay I, Zib I et al. Cardiac steatosis in diabetes mellitus: a 1H-magnetic resonance spectroscopy study. Circulation 2007; 116 (10): 1170–5.
12. Wende AR, Symons JD, Abel ED. Mechanisms of Lipotoxicity in the Cardiovascular System. Curr Hypertens Rep 2012; 14 (6): 517–31.
13. Stratford S, Hoehn KL, Liu F et al. Regulation of insulin action by ceramide: Dual mechanisms linking ceramide accumulation to the inhibition of akt/protein kinase b. J Biol Chem 2004; 279: 36608–15.
14. Son NH, Park TS, Yamashita H et al. Cardiomyocyte expression of ppargamma leads to cardiac dysfunction in mice. J Clin Invest 2007; 117: 2791–801.
15. Boudina S, Abel ED. Diabetic cardiomyopathy, causes and effects. Rev Endocr Metab Disord 2010; 11: 31–9.
16. Mewton N, Ying LC, Pierre С et al. Assessment of myocardial fibrosis with cardiac magnetic resonance. J Am Coll Cardiol 2011; 57 (8): 891–903.
17. Kwon DH, Halley CM, Popovic ZB et al. Gender differences in survival in patients with severe left ventricular dysfunction despite similar extent of myocardial scar measured on cardiac magnetic resonance. Eur J Heart Fail 2009; 11: 937–44.
18. Martos R, Baugh J, Ledwidge M et al. Diastolic heart failure: evidence of increased myocardial collagen turnover linked to diastolic dysfunction. Circulation 2007; 115: 888–895.
19. Lopez B, Gonzalez A, Beaumont J et al. Identification of a potential cardiac antifibrotic mechanism of torasemide in patients with chronic heart failure. J Am Coll Cardiol 2007; 50: 859–67.
20. Eguchi K, Boden-Albala B, Jin Z et al. Association between diabetes mellitus and left ventricular hypertrophy in a multiethnic population. Am J Cardiol 2008; 101 (12): 1787–91.
21. Woodiwiss AJ, Libhaber CD, Majane OH et al. Obesity promotes left ventricular concentric rather than eccentric geometric remodeling and hypertrophy independent of blood pressure. Am J Hypertens 2008; 21 (10): 1144–51.
22. Kim M, Oh JK, Sakata S et al. Role of resistin in cardiac contractility and hypertrophy. J Mol Cell Cardiol 2008; 45 (2): 270–80.
23. Bahrami H, Bluemke DA, Kronmal R et al. Novel metabolic risk factors for incident heart failure and their relationship with obesity: the MESA (Multi-Ethnic Study of Atherosclerosis) study. J Am Coll Cardiol 2008; 51 (18): 1775–83.
24. Brooks BA, Franjic B, Ban CR et al. Diastolic dysfunction and abnormalities of the microcirculation in type 2 diabetes. Diabetes Obes Metab 2008; 10 (9): 739–46.
25. Hsueh W, Abel ED, Breslow JL et al. Recipes for creating animal models of diabetic cardiovascular disease. Circ Res 2007; 100 (10): 1415–27.
26. Greulich S, De Wiza DH, Preilowksi S et al. Secretory products of guinea pig epicardial fat induce insulin resistance and impair primary adult rat cardiomyocyte function. J Cell Mol Med 2011; 15: 2399–410.
27. Huang G, Wang D, Zeb I et al. Intra-thoracic fat, cardiometabolic risk factors, and subclinical cardiovascular disease in healthy, recently menopausal women screened for the Kronos Early Estrogen Prevention Study (KEEPS). Atherosclerosis 2012; 221: 198–205.
28. Iacobellis G. Relation of epicardial fat thickness to right ventricular cavity size in obese subjects. Am J Cardiol 2009; 104 (11): 601–2. DOI: 10.1016/j.amjcard.2009.07.032.
29. Iacobellis G, Leonetti F, Singh N et al. Relationship of epicardial adipose tissue with atrial dimensions and diastolic function in morbidly obese subjects. Int J Cardiol 2007; 115 (2): 272–3.
30. Mookadam F, Goel R, Alharthi MS. Epicardial Fat and Its Association with Cardiovascular Risk: A Cross-Sectional Observational Study. Heart Views 2010; 11(3): 103–8.
31. Kilicaslan B, Ozdogan O, Aydin M et al. Increased epicardial fat thickness is associated with cardiac functional changes in healthy women. J Exp Med 2012; 228 (2): 119–24.
32. Веселовская Н.Г., Чумакова Г.А., Отт О.В. и др. Особенности ремоделирования миокарда и его функций у больных с эпикардиальным ожирением. Сердечная недостаточность. 2013; 5 (79): 247–51. / Veselovskaia N.G., Chumakova G.A., Ott O.V. i dr. Osobennosti remodelirovaniia miokarda i ego funktsii u bol'nykh s epikardial'nym ozhireniem. Serdechnaia nedostatochnost'. 2013; 5 (79): 247–51. [in Russian]
2. Wende AR, Abel ED. Lipotoxicity in the Heart. Biochim Biophys Acta 2010; 1801 (3): 311–9.
3. Astashkin E.I., Glezer M.G. Lipotoksicheskie effekty v sredtse, nabliudaemye pri ozhirenii. Arterial'naia gipertenziia. 2009; 15 (3): 335–41. [in Russian]
4. Ritchie RH. Evidence for a causal role of oxidative stress in the myocardial complications of insulin resistance. Heart Lung Circ 2009; 18 (1): 11–8.
5. Drosatos K, Schulze PC. Cardiac Lipotoxicity: Molecular Pathways and Therapeutic Implications. Curr Heart Fail Rep 2013; 10 (2): 109–21.
6. Nanayakkara G, Kariharan T, Wang L et al. The cardio-protective signaling and mechanisms of adiponectin. Am J Cardiovasc Dis 2012; 2 (4): 253–66.
7. Haffar T, Bérubé-Simard F, Bousette N. Impaired fatty acid oxidation as a cause for lipotoxicity in cardiomyocytes. Biochem Biophys Res Commun 2015; 468 (1–2): 73–8.
8. Augustus AS, Buchanan J, Park TS et al. Loss of lipoprotein lipase-derived fatty acids leads to increased cardiac glucose metabolism and heart dysfunction. J Biol Chem 2006; 281: 8716–23.
9. Drosatos K, Bharadwaj KG, Lymperopoulos A et al. Cardiomyocyte lipids impair beta-adrenergic receptor function via pkc activation. Am J Physiol Endocrinol Metab 2011; 300: E489–499.
10. Gaborti B, Kober F, Jacquier A et al. Assessment of epicardial fat volume and myocardial triglyceride content in severely obese subjects: relationship to metabolic profile, cardiac function and visceral fat. Int J Obes (Lond) 2012; 36 (3): 422–30.
11. McGavock JM, Lingvay I, Zib I et al. Cardiac steatosis in diabetes mellitus: a 1H-magnetic resonance spectroscopy study. Circulation 2007; 116 (10): 1170–5.
12. Wende AR, Symons JD, Abel ED. Mechanisms of Lipotoxicity in the Cardiovascular System. Curr Hypertens Rep 2012; 14 (6): 517–31.
13. Stratford S, Hoehn KL, Liu F et al. Regulation of insulin action by ceramide: Dual mechanisms linking ceramide accumulation to the inhibition of akt/protein kinase b. J Biol Chem 2004; 279: 36608–15.
14. Son NH, Park TS, Yamashita H et al. Cardiomyocyte expression of ppargamma leads to cardiac dysfunction in mice. J Clin Invest 2007; 117: 2791–801.
15. Boudina S, Abel ED. Diabetic cardiomyopathy, causes and effects. Rev Endocr Metab Disord 2010; 11: 31–9.
16. Mewton N, Ying LC, Pierre С et al. Assessment of myocardial fibrosis with cardiac magnetic resonance. J Am Coll Cardiol 2011; 57 (8): 891–903.
17. Kwon DH, Halley CM, Popovic ZB et al. Gender differences in survival in patients with severe left ventricular dysfunction despite similar extent of myocardial scar measured on cardiac magnetic resonance. Eur J Heart Fail 2009; 11: 937–44.
18. Martos R, Baugh J, Ledwidge M et al. Diastolic heart failure: evidence of increased myocardial collagen turnover linked to diastolic dysfunction. Circulation 2007; 115: 888–895.
19. Lopez B, Gonzalez A, Beaumont J et al. Identification of a potential cardiac antifibrotic mechanism of torasemide in patients with chronic heart failure. J Am Coll Cardiol 2007; 50: 859–67.
20. Eguchi K, Boden-Albala B, Jin Z et al. Association between diabetes mellitus and left ventricular hypertrophy in a multiethnic population. Am J Cardiol 2008; 101 (12): 1787–91.
21. Woodiwiss AJ, Libhaber CD, Majane OH et al. Obesity promotes left ventricular concentric rather than eccentric geometric remodeling and hypertrophy independent of blood pressure. Am J Hypertens 2008; 21 (10): 1144–51.
22. Kim M, Oh JK, Sakata S et al. Role of resistin in cardiac contractility and hypertrophy. J Mol Cell Cardiol 2008; 45 (2): 270–80.
23. Bahrami H, Bluemke DA, Kronmal R et al. Novel metabolic risk factors for incident heart failure and their relationship with obesity: the MESA (Multi-Ethnic Study of Atherosclerosis) study. J Am Coll Cardiol 2008; 51 (18): 1775–83.
24. Brooks BA, Franjic B, Ban CR et al. Diastolic dysfunction and abnormalities of the microcirculation in type 2 diabetes. Diabetes Obes Metab 2008; 10 (9): 739–46.
25. Hsueh W, Abel ED, Breslow JL et al. Recipes for creating animal models of diabetic cardiovascular disease. Circ Res 2007; 100 (10): 1415–27.
26. Greulich S, De Wiza DH, Preilowksi S et al. Secretory products of guinea pig epicardial fat induce insulin resistance and impair primary adult rat cardiomyocyte function. J Cell Mol Med 2011; 15: 2399–410.
27. Huang G, Wang D, Zeb I et al. Intra-thoracic fat, cardiometabolic risk factors, and subclinical cardiovascular disease in healthy, recently menopausal women screened for the Kronos Early Estrogen Prevention Study (KEEPS). Atherosclerosis 2012; 221: 198–205.
28. Iacobellis G. Relation of epicardial fat thickness to right ventricular cavity size in obese subjects. Am J Cardiol 2009; 104 (11): 601–2. DOI: 10.1016/j.amjcard.2009.07.032.
29. Iacobellis G, Leonetti F, Singh N et al. Relationship of epicardial adipose tissue with atrial dimensions and diastolic function in morbidly obese subjects. Int J Cardiol 2007; 115 (2): 272–3.
30. Mookadam F, Goel R, Alharthi MS. Epicardial Fat and Its Association with Cardiovascular Risk: A Cross-Sectional Observational Study. Heart Views 2010; 11(3): 103–8.
31. Kilicaslan B, Ozdogan O, Aydin M et al. Increased epicardial fat thickness is associated with cardiac functional changes in healthy women. J Exp Med 2012; 228 (2): 119–24.
32. Veselovskaia N.G., Chumakova G.A., Ott O.V. i dr. Osobennosti remodelirovaniia miokarda i ego funktsii u bol'nykh s epikardial'nym ozhireniem. Serdechnaia nedostatochnost'. 2013; 5 (79): 247–51. [in Russian]
2. Wende AR, Abel ED. Lipotoxicity in the Heart. Biochim Biophys Acta 2010; 1801 (3): 311–9.
3. Асташкин Е.И., Глезер М.Г. Липотоксические эффекты в средце, наблюдаемые при ожирении. Артериальная гипертензия. 2009; 15 (3): 335–41. / Astashkin E.I., Glezer M.G. Lipotoksicheskie effekty v sredtse, nabliudaemye pri ozhirenii. Arterial'naia gipertenziia. 2009; 15 (3): 335–41. [in Russian]
4. Ritchie RH. Evidence for a causal role of oxidative stress in the myocardial complications of insulin resistance. Heart Lung Circ 2009; 18 (1): 11–8.
5. Drosatos K, Schulze PC. Cardiac Lipotoxicity: Molecular Pathways and Therapeutic Implications. Curr Heart Fail Rep 2013; 10 (2): 109–21.
6. Nanayakkara G, Kariharan T, Wang L et al. The cardio-protective signaling and mechanisms of adiponectin. Am J Cardiovasc Dis 2012; 2 (4): 253–66.
7. Haffar T, Bérubé-Simard F, Bousette N. Impaired fatty acid oxidation as a cause for lipotoxicity in cardiomyocytes. Biochem Biophys Res Commun 2015; 468 (1–2): 73–8.
8. Augustus AS, Buchanan J, Park TS et al. Loss of lipoprotein lipase-derived fatty acids leads to increased cardiac glucose metabolism and heart dysfunction. J Biol Chem 2006; 281: 8716–23.
9. Drosatos K, Bharadwaj KG, Lymperopoulos A et al. Cardiomyocyte lipids impair beta-adrenergic receptor function via pkc activation. Am J Physiol Endocrinol Metab 2011; 300: E489–499.
10. Gaborti B, Kober F, Jacquier A et al. Assessment of epicardial fat volume and myocardial triglyceride content in severely obese subjects: relationship to metabolic profile, cardiac function and visceral fat. Int J Obes (Lond) 2012; 36 (3): 422–30.
11. McGavock JM, Lingvay I, Zib I et al. Cardiac steatosis in diabetes mellitus: a 1H-magnetic resonance spectroscopy study. Circulation 2007; 116 (10): 1170–5.
12. Wende AR, Symons JD, Abel ED. Mechanisms of Lipotoxicity in the Cardiovascular System. Curr Hypertens Rep 2012; 14 (6): 517–31.
13. Stratford S, Hoehn KL, Liu F et al. Regulation of insulin action by ceramide: Dual mechanisms linking ceramide accumulation to the inhibition of akt/protein kinase b. J Biol Chem 2004; 279: 36608–15.
14. Son NH, Park TS, Yamashita H et al. Cardiomyocyte expression of ppargamma leads to cardiac dysfunction in mice. J Clin Invest 2007; 117: 2791–801.
15. Boudina S, Abel ED. Diabetic cardiomyopathy, causes and effects. Rev Endocr Metab Disord 2010; 11: 31–9.
16. Mewton N, Ying LC, Pierre С et al. Assessment of myocardial fibrosis with cardiac magnetic resonance. J Am Coll Cardiol 2011; 57 (8): 891–903.
17. Kwon DH, Halley CM, Popovic ZB et al. Gender differences in survival in patients with severe left ventricular dysfunction despite similar extent of myocardial scar measured on cardiac magnetic resonance. Eur J Heart Fail 2009; 11: 937–44.
18. Martos R, Baugh J, Ledwidge M et al. Diastolic heart failure: evidence of increased myocardial collagen turnover linked to diastolic dysfunction. Circulation 2007; 115: 888–895.
19. Lopez B, Gonzalez A, Beaumont J et al. Identification of a potential cardiac antifibrotic mechanism of torasemide in patients with chronic heart failure. J Am Coll Cardiol 2007; 50: 859–67.
20. Eguchi K, Boden-Albala B, Jin Z et al. Association between diabetes mellitus and left ventricular hypertrophy in a multiethnic population. Am J Cardiol 2008; 101 (12): 1787–91.
21. Woodiwiss AJ, Libhaber CD, Majane OH et al. Obesity promotes left ventricular concentric rather than eccentric geometric remodeling and hypertrophy independent of blood pressure. Am J Hypertens 2008; 21 (10): 1144–51.
22. Kim M, Oh JK, Sakata S et al. Role of resistin in cardiac contractility and hypertrophy. J Mol Cell Cardiol 2008; 45 (2): 270–80.
23. Bahrami H, Bluemke DA, Kronmal R et al. Novel metabolic risk factors for incident heart failure and their relationship with obesity: the MESA (Multi-Ethnic Study of Atherosclerosis) study. J Am Coll Cardiol 2008; 51 (18): 1775–83.
24. Brooks BA, Franjic B, Ban CR et al. Diastolic dysfunction and abnormalities of the microcirculation in type 2 diabetes. Diabetes Obes Metab 2008; 10 (9): 739–46.
25. Hsueh W, Abel ED, Breslow JL et al. Recipes for creating animal models of diabetic cardiovascular disease. Circ Res 2007; 100 (10): 1415–27.
26. Greulich S, De Wiza DH, Preilowksi S et al. Secretory products of guinea pig epicardial fat induce insulin resistance and impair primary adult rat cardiomyocyte function. J Cell Mol Med 2011; 15: 2399–410.
27. Huang G, Wang D, Zeb I et al. Intra-thoracic fat, cardiometabolic risk factors, and subclinical cardiovascular disease in healthy, recently menopausal women screened for the Kronos Early Estrogen Prevention Study (KEEPS). Atherosclerosis 2012; 221: 198–205.
28. Iacobellis G. Relation of epicardial fat thickness to right ventricular cavity size in obese subjects. Am J Cardiol 2009; 104 (11): 601–2. DOI: 10.1016/j.amjcard.2009.07.032.
29. Iacobellis G, Leonetti F, Singh N et al. Relationship of epicardial adipose tissue with atrial dimensions and diastolic function in morbidly obese subjects. Int J Cardiol 2007; 115 (2): 272–3.
30. Mookadam F, Goel R, Alharthi MS. Epicardial Fat and Its Association with Cardiovascular Risk: A Cross-Sectional Observational Study. Heart Views 2010; 11(3): 103–8.
31. Kilicaslan B, Ozdogan O, Aydin M et al. Increased epicardial fat thickness is associated with cardiac functional changes in healthy women. J Exp Med 2012; 228 (2): 119–24.
32. Веселовская Н.Г., Чумакова Г.А., Отт О.В. и др. Особенности ремоделирования миокарда и его функций у больных с эпикардиальным ожирением. Сердечная недостаточность. 2013; 5 (79): 247–51. / Veselovskaia N.G., Chumakova G.A., Ott O.V. i dr. Osobennosti remodelirovaniia miokarda i ego funktsii u bol'nykh s epikardial'nym ozhireniem. Serdechnaia nedostatochnost'. 2013; 5 (79): 247–51. [in Russian]
________________________________________________
2. Wende AR, Abel ED. Lipotoxicity in the Heart. Biochim Biophys Acta 2010; 1801 (3): 311–9.
3. Astashkin E.I., Glezer M.G. Lipotoksicheskie effekty v sredtse, nabliudaemye pri ozhirenii. Arterial'naia gipertenziia. 2009; 15 (3): 335–41. [in Russian]
4. Ritchie RH. Evidence for a causal role of oxidative stress in the myocardial complications of insulin resistance. Heart Lung Circ 2009; 18 (1): 11–8.
5. Drosatos K, Schulze PC. Cardiac Lipotoxicity: Molecular Pathways and Therapeutic Implications. Curr Heart Fail Rep 2013; 10 (2): 109–21.
6. Nanayakkara G, Kariharan T, Wang L et al. The cardio-protective signaling and mechanisms of adiponectin. Am J Cardiovasc Dis 2012; 2 (4): 253–66.
7. Haffar T, Bérubé-Simard F, Bousette N. Impaired fatty acid oxidation as a cause for lipotoxicity in cardiomyocytes. Biochem Biophys Res Commun 2015; 468 (1–2): 73–8.
8. Augustus AS, Buchanan J, Park TS et al. Loss of lipoprotein lipase-derived fatty acids leads to increased cardiac glucose metabolism and heart dysfunction. J Biol Chem 2006; 281: 8716–23.
9. Drosatos K, Bharadwaj KG, Lymperopoulos A et al. Cardiomyocyte lipids impair beta-adrenergic receptor function via pkc activation. Am J Physiol Endocrinol Metab 2011; 300: E489–499.
10. Gaborti B, Kober F, Jacquier A et al. Assessment of epicardial fat volume and myocardial triglyceride content in severely obese subjects: relationship to metabolic profile, cardiac function and visceral fat. Int J Obes (Lond) 2012; 36 (3): 422–30.
11. McGavock JM, Lingvay I, Zib I et al. Cardiac steatosis in diabetes mellitus: a 1H-magnetic resonance spectroscopy study. Circulation 2007; 116 (10): 1170–5.
12. Wende AR, Symons JD, Abel ED. Mechanisms of Lipotoxicity in the Cardiovascular System. Curr Hypertens Rep 2012; 14 (6): 517–31.
13. Stratford S, Hoehn KL, Liu F et al. Regulation of insulin action by ceramide: Dual mechanisms linking ceramide accumulation to the inhibition of akt/protein kinase b. J Biol Chem 2004; 279: 36608–15.
14. Son NH, Park TS, Yamashita H et al. Cardiomyocyte expression of ppargamma leads to cardiac dysfunction in mice. J Clin Invest 2007; 117: 2791–801.
15. Boudina S, Abel ED. Diabetic cardiomyopathy, causes and effects. Rev Endocr Metab Disord 2010; 11: 31–9.
16. Mewton N, Ying LC, Pierre С et al. Assessment of myocardial fibrosis with cardiac magnetic resonance. J Am Coll Cardiol 2011; 57 (8): 891–903.
17. Kwon DH, Halley CM, Popovic ZB et al. Gender differences in survival in patients with severe left ventricular dysfunction despite similar extent of myocardial scar measured on cardiac magnetic resonance. Eur J Heart Fail 2009; 11: 937–44.
18. Martos R, Baugh J, Ledwidge M et al. Diastolic heart failure: evidence of increased myocardial collagen turnover linked to diastolic dysfunction. Circulation 2007; 115: 888–895.
19. Lopez B, Gonzalez A, Beaumont J et al. Identification of a potential cardiac antifibrotic mechanism of torasemide in patients with chronic heart failure. J Am Coll Cardiol 2007; 50: 859–67.
20. Eguchi K, Boden-Albala B, Jin Z et al. Association between diabetes mellitus and left ventricular hypertrophy in a multiethnic population. Am J Cardiol 2008; 101 (12): 1787–91.
21. Woodiwiss AJ, Libhaber CD, Majane OH et al. Obesity promotes left ventricular concentric rather than eccentric geometric remodeling and hypertrophy independent of blood pressure. Am J Hypertens 2008; 21 (10): 1144–51.
22. Kim M, Oh JK, Sakata S et al. Role of resistin in cardiac contractility and hypertrophy. J Mol Cell Cardiol 2008; 45 (2): 270–80.
23. Bahrami H, Bluemke DA, Kronmal R et al. Novel metabolic risk factors for incident heart failure and their relationship with obesity: the MESA (Multi-Ethnic Study of Atherosclerosis) study. J Am Coll Cardiol 2008; 51 (18): 1775–83.
24. Brooks BA, Franjic B, Ban CR et al. Diastolic dysfunction and abnormalities of the microcirculation in type 2 diabetes. Diabetes Obes Metab 2008; 10 (9): 739–46.
25. Hsueh W, Abel ED, Breslow JL et al. Recipes for creating animal models of diabetic cardiovascular disease. Circ Res 2007; 100 (10): 1415–27.
26. Greulich S, De Wiza DH, Preilowksi S et al. Secretory products of guinea pig epicardial fat induce insulin resistance and impair primary adult rat cardiomyocyte function. J Cell Mol Med 2011; 15: 2399–410.
27. Huang G, Wang D, Zeb I et al. Intra-thoracic fat, cardiometabolic risk factors, and subclinical cardiovascular disease in healthy, recently menopausal women screened for the Kronos Early Estrogen Prevention Study (KEEPS). Atherosclerosis 2012; 221: 198–205.
28. Iacobellis G. Relation of epicardial fat thickness to right ventricular cavity size in obese subjects. Am J Cardiol 2009; 104 (11): 601–2. DOI: 10.1016/j.amjcard.2009.07.032.
29. Iacobellis G, Leonetti F, Singh N et al. Relationship of epicardial adipose tissue with atrial dimensions and diastolic function in morbidly obese subjects. Int J Cardiol 2007; 115 (2): 272–3.
30. Mookadam F, Goel R, Alharthi MS. Epicardial Fat and Its Association with Cardiovascular Risk: A Cross-Sectional Observational Study. Heart Views 2010; 11(3): 103–8.
31. Kilicaslan B, Ozdogan O, Aydin M et al. Increased epicardial fat thickness is associated with cardiac functional changes in healthy women. J Exp Med 2012; 228 (2): 119–24.
32. Veselovskaia N.G., Chumakova G.A., Ott O.V. i dr. Osobennosti remodelirovaniia miokarda i ego funktsii u bol'nykh s epikardial'nym ozhireniem. Serdechnaia nedostatochnost'. 2013; 5 (79): 247–51. [in Russian]
Авторы
О.В.Гриценко1,2, Г.А.Чумакова*2,3, С.А.Ельчанинова3, Н.Г.Веселовская1,2, И.В.Шевляков1, О.А.Калугина1
1 КГБУЗ «Алтайский краевой кардиологический диспансер». 656055, Россия, Барнаул, ул. Малахова, д. 46;
2 ФГБНУ «Научно-исследовательский институт комплексных проблем сердечно-сосудистых заболеваний». 650002, Россия, Кемерово, Сосновый бул., д. 6;
3 ФГБОУ ВО «Алтайский государственный медицинский университет» Минздрава России. 656038, Россия, Барнаул, пр-т Ленина, д. 40
*g.a.chumakova@mail.ru
1 Altay Regional Cardiological Dispensary. 656055, Russian Federation, Barnaul, ul. Malakhova, d. 46;
2 Science Research Institute for Complex Issues of Cardiovascular Diseases. 650002, Russian Federation, Kemerovo, Sosnovyi bul., d. 6;
3 Altay State Medical University of the Ministry of Health of the Russian Federation. 656038, Russian Federation, Barnaul, pr-t Lenina, d. 40
*g.a.chumakova@mail.ru
1 КГБУЗ «Алтайский краевой кардиологический диспансер». 656055, Россия, Барнаул, ул. Малахова, д. 46;
2 ФГБНУ «Научно-исследовательский институт комплексных проблем сердечно-сосудистых заболеваний». 650002, Россия, Кемерово, Сосновый бул., д. 6;
3 ФГБОУ ВО «Алтайский государственный медицинский университет» Минздрава России. 656038, Россия, Барнаул, пр-т Ленина, д. 40
*g.a.chumakova@mail.ru
________________________________________________
1 Altay Regional Cardiological Dispensary. 656055, Russian Federation, Barnaul, ul. Malakhova, d. 46;
2 Science Research Institute for Complex Issues of Cardiovascular Diseases. 650002, Russian Federation, Kemerovo, Sosnovyi bul., d. 6;
3 Altay State Medical University of the Ministry of Health of the Russian Federation. 656038, Russian Federation, Barnaul, pr-t Lenina, d. 40
*g.a.chumakova@mail.ru
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.